Full-Time

Business Development Representative

Business Development

Zeiss

Zeiss

1,001-5,000 employees

Manufactures high-precision optical instruments and devices

Compensation Overview

$82.5k/yr

+ Commission

Company Does Not Provide H1B Sponsorship

Denver, CO, USA

Remote

Must reside in South Metro Denver or Denver, Colorado.

Bachelor's

Category
Business & Strategy (1)
Required Skills
Salesforce

Get referred to Zeiss

See people who can refer or advise you

Requirements
  • S or BA in Business, Public Administration, Marketing, or related field strongly preferred.
  • 2+ years in a successful business to business sales environment, preferably in Rx sales, optical, medical device, or retail operations industry with Fortune 500 companies strongly preferred.
  • Strong sales focus with the ability to move key opportunities through the sales cycle, providing detailed and accurate sales forecasts using the company's CRM tool.
  • Ability to thrive in a competitive environment.
  • Demonstrated experience in creating plans to achieve revenue and profitability goals.
  • Effective consultative, conceptual and negotiation skills with demonstrated ability to establish influential relationships with customers.
  • Disciplined and results-oriented approach to selling and strong time management skills.
  • Demonstrated ability to operate as a team player and able to work collaboratively with and through others.
  • Ability to influence situations and people.
  • Self-starter with the ability to work independently.
  • Must have a valid driver’s license.
  • Demonstrated ability to be proficient with standard MS Office applications, company technology devices (Laptop, iPad, iPhone, etc.) for territory management and product orders.
Responsibilities
  • Meet or exceed sales growth targets for Direct Rx business and other strategic targets such as premium lenses, coatings, finished single vision lenses and organizational programs and projects.
  • Utilize Salesforce.com to identify key customer targets to increase territory sales.
  • Profile and evaluate each customer’s store operation, financial data, business model & profit drivers, and create value-based sales strategies that has positive financial impact on company.
  • Conduct and prepare pre-call planning and call objectives, and anticipate likely objections; understand motivations and establish a relationship as a trusted advisor / consultant.
  • Lead sales conversation with ECPs by challenging and persuading them to change behavior. Build agreement at each point in the sales process, remove barriers and close the deal.
  • Create innovative tactical and strategic approaches to meet and exceed business objectives when faced with an obstacle or a customer concern.
  • Increase sales by effectively communicating the advantages and benefits of Carl Zeiss Vision products and services to Eye Care Professionals.
  • Support and implements national marketing plans, utilizing digital tools and apps.
  • Schedule, plan, develop and conduct on-site individual, group and office training and educational seminars to increase demand for Carl Zeiss Vision labs and lenses.
  • Work with Alliance Groups to maximize opportunities to grow CZV share within assigned territory.
  • Establish a positive, productive and collaborate working relationships with Carl Zeiss Vision employees and colleagues.
  • Operate with the highest ethical standard during every customer interaction and in alignment with Carl Zeiss philosophies and leadership principles.
  • Input accurate and timely reports via Salesforce.com.
  • Efficiently manage travel cost and leverage smart spending techniques.
  • Prepare and submit timely expense reports.
  • Follows safety standards and reports any safety concerns to leadership.
Desired Qualifications
  • ABO and/or optical experience preferred.
  • Knowledge of Salesforce.com preferred.

ZEISS is a global leader in optics and optoelectronics, serving medical professionals, industrial manufacturers, consumers, and the semiconductor industry. It designs and sells high-precision optical instruments, medical devices, semiconductor manufacturing equipment, and vision care products such as corrective lenses and eye-health services. Its products rely on advanced optics and imaging technologies to deliver accurate inspection, diagnosis, and manufacturing outcomes across healthcare, industrial quality control, consumer optics, and chip fabrication. What sets ZEISS apart is its breadth and depth: a long-standing scale in multiple markets, integrated solutions across optics, imaging, metrology, and precision engineering, and a commitment to sustainability in electricity use and carbon emissions. The company’s goal is to advance optics and optoelectronics by providing reliable, high-quality tools and services worldwide while operating in a sustainable way.

Company Size

1,001-5,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$1.1B

Headquarters

Oberkochen, Germany

Founded

2001

Get referred to Zeiss

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ZEISS won Mexico COFEPRIS approval in 2026 for ARTEVO 850 and MICOR 700.
  • ZEISS launched VisioGen commercially in the US at ASCRS 2026, expanding recurring software sales.
  • August 6, 2026 meditec nine-month results showed stable currency-adjusted revenue momentum.

What critics are saying

  • ZEISS announced June 9, 2026 cost cuts and expected job reductions across segments.
  • Carl Zeiss Meditec targets over €200 million annual savings through 2028/29, signaling pressure.
  • Medical Technology revenue fell 7% in first half fiscal 2025/26, exposing dependence on semiconductors.

What makes Zeiss unique

  • Foundation-owned ZEISS spans semiconductors, ophthalmology, and metrology under one capital structure.
  • ZEISS Semiconductor Manufacturing Technology grew 6% in first half fiscal 2025/26, driven by EUV optics.
  • ZEISS owns the IOLMaster, ARTEVO, and FORUM workflow stack across cataract care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Paid Vacation

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

4%

2 year growth

4%
ZEISS
Aug 5th, 2026
ZEISS leads $2.5M investment in SeeTrue Technologies for miniaturised eye-tracking tech

ZEISS Ventures led a €2.2 million investment round in SeeTrue Technologies, a Finnish deep-tech company developing miniaturised eye-tracking technology. The funding will accelerate commercialisation of SeeTrue's ultra-low-power eye-sensing architecture for next-generation interfaces in smart optical systems and eyewear. SeeTrue's proprietary technology combines miniaturised sensing hardware with optimised embedded processing, enabling scalable eye-sensing capabilities with low power consumption and small hardware footprint. The technology supports gaze-based interaction and attention-aware computing across healthcare, industrial, and smart eyewear applications. The investment round includes participation from Superhero Capital and North Karelia Growth Fund, managed by Redstone Nordics. Founded in 2018 and based in Joensuu, Finland, SeeTrue develops ultra-miniature eye-tracking technology for medical optical systems, vision care, and smart wearables.

PR Newswire
Jun 11th, 2026
ZEISS completes early implantations of AT LUCIA toric 721P intraocular lens

ZEISS Medical Technology has announced successful early clinical implantations of its AT LUCIA toric 721P intraocular lens, designed to treat cataracts whilst correcting astigmatism. The company is conducting an early-access clinical trial with experienced surgeons across six European countries. The lens combines an aspheric bitoric optic with a patented non-constant aberration design on a fully preloaded, hydrophobic platform. Surgeons have reported positive early impressions, highlighting the lens's precision, stability and surgical handling. Currently CE marked, the AT LUCIA toric 721P will be showcased at the International Congress of German Ophthalmic Surgery in Nuremberg from 18–20 June 2026. The lens is expected to be commercially available in select European countries later this year.

ZEISS
May 28th, 2026
ZEISS invests in Maculaser to advance temperature-controlled retinal laser therapy

ZEISS Ventures has invested in Maculaser, a Finnish medtech company developing temperature-controlled retinal laser therapy, through a funding round co-led with M2care. The investment will support clinical development of the company's personalized treatment for retinal diseases. Founded in 2020 and based on research from Aalto University, Maculaser has developed patented technology that provides real-time temperature control during laser treatment. The non-damaging approach activates natural cellular defence mechanisms, targeting affected retinal areas early to delay or prevent progression of age-related macular degeneration and diabetic maculopathy. The technology aims to shift retinal care from managing late-stage damage to proactive vision preservation, offering an outpatient procedure that integrates into regular eye care. Maculaser plans to bring the treatment into clinical practice to benefit millions of patients worldwide.

PR Newswire
May 13th, 2026
ZEISS gains COFEPRIS approval for ARTEVO 850 and MICOR 700 ophthalmic surgical systems in Mexico

ZEISS Medical Technology has received approval from Mexico's COFEPRIS for two ophthalmic surgical devices: the ARTEVO 850 microscope and MICOR 700 lens removal device. Both technologies are compatible with ZEISS's latest cataract workflow systems. The ARTEVO 850 is a 3D heads-up ophthalmic microscope offering true colour imaging and a nearly 60% increase in depth of field. The MICOR 700 is the first handheld lens removal device with ultrasound-free operation, using ZEISS's non-ultrasonic lens extraction procedure to minimise risk to surrounding eye structures. The products will be showcased at the Mexican Congress of Ophthalmology in Monterrey from 30 May to 3 June 2026. ZEISS Medical Technology generated revenue of €2,066.1 million in fiscal year 2023/24.

Gridley Herald
Apr 29th, 2026
Hypervision Surgical raises $21.6M Series A for AI-assisted surgery platform

Hypervision Surgical, a UK-based pioneer in real-time hyperspectral imaging for surgery, has raised £17 million in an oversubscribed Series A round led by Heal Capital. Angelini Ventures participated alongside IP Group and Daycrest, with Angelini Ventures Managing Director Tanja Dowe joining the board. The King's College London spin-out has developed the Hyperspectral Intelligence platform, which combines hyperspectral sensing with AI-driven analytics to provide real-time, quantitative insights into tissue physiology during surgery. The technology captures information beyond what conventional surgical cameras can perceive, potentially improving intraoperative decision-making and reducing complications. The funding will support commercial deployment, clinical adoption and development of next-generation hyperspectral sensing technology. The company's HYPERSNAP system is certified in the UK and cleared by the US FDA.